Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ddcb41d2adaefbfa326bb6fee4de313e |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-241 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39591 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-183 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39591 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00 |
filingDate |
2017-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_747e6dca18b0782849ca366619ab125f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c2888201550def1fe90e3d5b22f13fb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_11a70cc1f0304ff9e57e69bddfffd945 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_45afaf0460b65022b33cb55bfe6c24e3 |
publicationDate |
2019-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-3563867-A1 |
titleOfInvention |
Aqueous pharmaceutical composition of a recombinant monoclonal antibody to tnf alfa |
abstract |
The invention relates to improved aqueous pharmaceutical compositions of a recombinant monoclonal antibody to TNFa, and to a method for producing same. The present invention also relates to the use of improved aqueous pharmaceutical compositions of a recombinant monoclonal antibody to TNFa to treat TNFa-mediated diseases. The proposed invention allows prevention of physical-chemical instability expressed in the formation of aggregates and fragments of proteins or in the modification of proteins in a solution, and also prevents instability during freezing/thawing, agitating and shaking. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021182874-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021246921-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2745814-C1 |
priorityDate |
2016-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |